Esophageal Cancer

Pathophysiology

---

Esophageal cancer primarily manifests as two histological subtypes:

Both subtypes share a multistep carcinogenic process involving chronic mucosal injury, inflammation, dysplasia, and eventual malignant transformation. Tumor progression leads to local invasion, lymphatic spread, and distant metastases, most commonly to the liver, lungs, and bones.

Epidemiology of Esophageal Cancer

---

Incidence and Prevalence

• In 2020, there were an estimated 604,000 new cases and 544,000 deaths from esophageal cancer globally.
• Age-standardized incidence rates (ASIR) are highest in Eastern Asia, Southern and Eastern Africa, and parts of South-Central Asia.
• In the United States:
  • Annual incidence is approximately 3–6 cases per 100,000 population.
  • The age-adjusted incidence rate is 4.2 per 100,000 for men and women.
  • Esophageal cancer accounts for about 1% of all diagnosed cancers.

Geographical Distribution

• Around 80% of global cases and deaths occur in Asia.
• China alone accounted for over half of all new cases in 2020 (324,422 cases).
• The “esophageal cancer belt” includes high-risk regions from northern Iran through Central Asia to northern China.
• Incidence is lowest in Western Asia, Northern and Western Africa, and Central America.

Sex and Age Distribution

• Esophageal cancer is more common in men than women:
  • Global male-to-female ratio: 2–3:1.
  • In the US, the ratio exceeds 4:1.
• It primarily affects older adults:
  • Median age at diagnosis: 68–70 years.
  • Incidence increases sharply after age 60.
  • Over 90% of deaths occur in those older than 55 years.

Histological Subtypes and Demographic Patterns

• The two main histological types are:
  • Squamous Cell Carcinoma (SCC):
    • Most prevalent globally.
    • Common in Asia and Africa.
  • Adenocarcinoma (AC):
    • Now dominant in Western countries.
    • Most frequent among White males in the US.
• In the US:
  • AC is more common in White populations.
  • SCC is more common in African Americans.

Trends and Projections

• Global incidence and mortality are expected to rise due to aging and population growth.
  • By 2040: nearly 988,000 new cases and over 914,000 deaths projected.
• In the US:
  • Adenocarcinoma incidence rose sharply from the 1970s to early 2000s but has recently plateaued or slightly declined.
  • SCC incidence has declined, likely due to reduced tobacco and alcohol consumption.

Risk Factors for Esophageal Cancer

---

Hereditary Factors

• Familial clustering is noted, especially in high-incidence SCC regions (e.g., China).
• Familial Barrett’s Esophagus (BE) is documented but its hereditary component remains unclear.
• Discordant data from Sweden and the US suggest environmental influences may dominate.

Genetic Syndromes Associated with Increased Risk:

• Peutz-Jeghers Syndrome: Elevated risk for GEJ cancers.
• PTEN Hamartoma Tumor Syndromes: Rare esophageal cancer cases in Cowden syndrome.

---

Squamous Cell Carcinoma (SCC)

Major Risk Factors

• Smoking, alcohol, low intake of fruits/vegetables contribute to ~90% of US SCC cases.
• In high-risk Asian regions: Poor nutrition, hot beverage consumption, environmental toxins.

HPV Infection

• May contribute to SCC pathogenesis.
• Meta-analyses show modest association but low prevalence.

Demographic and Socioeconomic Factors

• In high-incidence areas, SCC affects both sexes equally.
• In low-incidence regions, males are more affected.
• Higher incidence in Black males in urban US (e.g., 28.6/100,000 in Washington D.C.).
• Low socioeconomic status is a known risk factor.

Smoking and Alcohol

• Strong synergistic effect between tobacco and alcohol.
• Risk extends to other aerodigestive tract cancers (head, neck, lung).
• Hard liquor may carry higher risk than beer/wine.

Dietary Factors

• Carcinogens: N-nitroso compounds, pickled vegetables, aflatoxins.
• Risky practices: Areca nut chewing, drinking very hot tea or soup.
• Other factors:
  • High red meat intake
  • Selenium and zinc deficiencies
  • Low folate intake
  • Low fruit and vegetable intake

Underlying Esophageal Diseases

• Achalasia: >16-fold increased SCC risk.
• Caustic Strictures: Average 41 years latency post-injury.
• Atrophic Gastritis: Doubles SCC risk.
• Prior Gastrectomy: Potential link, though not consistently supported.

Tylosis

• Rare genetic disorder (Howel-Evans syndrome) with high SCC risk.
• Autosomal dominant mutation in RHBDF2 gene.
• Endoscopic surveillance recommended from age 30.

Bisphosphonates

• Oral bisphosphonates (e.g., alendronate) linked to esophageal irritation and possible malignancy.
• Not recommended for patients with BE.

Upper Aerodigestive Tract Cancers

• Shared risk factors result in 3–14% rate of synchronous or metachronous SCC in esophagus.
• Screening often recommended for high-risk groups.

Poor Oral Hygiene

• Associated with SCC in non-smoking/non-drinking populations (e.g., China, Iran, Kashmir).

---

Adenocarcinoma

Major Risk Factors

• GERD and Barrett’s Esophagus: Causes metaplasia and cancer
• Smoking: Doubles risk
• Obesity: Increases GERD risk and inflammation

Diet and Prevention

• Low fruits/vegetables increase risk
• Fiber, folate, vitamins protective
• High animal protein increases risk

Medications

• Aspirin reduces risk
• Nitrates/benzodiazepines may increase risk

Other Factors

• HPV: Possible link to Barrett’s
• Cholecystectomy: Slight risk from bile reflux
• H. pylori: Inversely associated with cancer risk

Clinical Manifestations

---

General Presentation

• Advanced thoracic or cervical esophageal carcinoma presents with:
  • Progressive dysphagia
  • Weight loss
  • Chronic gastrointestinal blood loss
  • Possible iron deficiency anemia
• Early intramucosal adenocarcinomas (especially in the distal esophagus associated with Barrett’s esophagus) are usually asymptomatic.

---

Thoracic Esophageal Tumors

• Both adenocarcinoma and squamous cell carcinoma (SCC) of the thoracic esophagus present similarly.
• Asymptomatic cases at diagnosis occur in 6–10% of patients.
• Early superficial cancers are often discovered incidentally or during surveillance for Barrett’s esophagus.
• These early cancers are not symptomatic.

---

Dysphagia and Weight Loss

• Progressive dysphagia is the most common symptom.
  • Occurs when the esophageal lumen narrows to <13 mm.
  • Indicates at least locally advanced disease.
• Weight loss results from:
  • Altered dietary habits
  • Tumor-induced anorexia
• Odynophagia (painful swallowing) affects ~20% of patients.
• Early nonspecific symptoms:
  • Transient food sticking
  • Retrosternal discomfort
  • Burning sensation
  • Gradual dysphagia progression: solids → liquids

---

Differential Diagnosis

• Dysphagia causes:
  • Benign strictures
  • Achalasia
  • Esophageal motility disorders
  • Esophagitis
  • Esophageal webs and rings
• Esophageal mass differential:
  • Gastrointestinal stromal tumors
  • Leiomyomas, leiomyosarcomas
  • High-grade neuroendocrine neoplasms (e.g., small cell cancers)

---

Other Symptoms

• Regurgitation of saliva or food (without gastric contents)
• Infrequent aspiration pneumonia
• Hoarseness or cough due to recurrent laryngeal nerve invasion
• Chronic blood loss may lead to:
  • Iron deficiency anemia
  • Rarely melena, hematemesis, or blood in regurgitation
• Acute bleeding due to arterial erosion is rare
• Tracheobronchial fistulas (late complication):
  • Due to tumor invasion into the bronchus
  • Symptoms: severe coughing, recurrent pneumonia
  • Treatment: stent placement

---

Metastatic Disease

• Common metastatic sites:
  • Liver
  • Lungs
  • Bones
  • Adrenal glands
• Adenocarcinomas: often spread intraabdominally (liver, peritoneum)
• SCCs: typically spread intrathoracically
• Other possible sites:
  • Skin
  • Muscle
  • Brain

---

Cervical Esophageal Tumors

• Represent 5–6% of esophageal cancers
• Located in the 6–8 cm segment from hypopharynx to sternal notch
• Often diagnosed as locally advanced disease, with possible hypopharyngeal extension
• Most common symptoms:
  • Weight loss
  • Dysphagia
  • Hoarseness (11–24% of cases)

Diagnosis

---

Histologic Confirmation

• Required for the diagnosis of esophageal cancer.
• Can be obtained via:
  • Upper endoscopy
  • Image-guided biopsy of a metastatic site (if present)

---

Endoscopic Biopsy

• Early cancers may appear as:
  • Superficial plaques
  • Nodules
  • Ulcerations
• Advanced lesions may present as:
  • Strictures
  • Ulcerated or circumferential masses
  • Large ulcerations
• Visualization suggests cancer, but biopsy is necessary for confirmation.
• Diagnostic accuracy increases with the number of biopsies:
  • 1 biopsy: 93%
  • 4 biopsies: 95%
  • 7 biopsies: 98%
• Small lesions may be resected endoscopically and analyzed histologically.

---

Pretreatment Staging Evaluation

• Accurate staging is essential for prognosis and treatment planning.

Staging Components

• Endoscopic Ultrasound (EUS) – Preferred for locoregional staging
• Bronchoscopy – For tumors at or above the carina
• Flexible Laryngoscopy – For cervical SCC to assess spread and rule out synchronous head and neck malignancy
• Contrast-enhanced CT – Neck, chest, and abdomen
• FDG-PET/CT – For detecting distant metastases
• Diagnostic Laparoscopy – In selected patients to confirm or rule out metastases

---

TNM Staging Criteria

• Based on AJCC/UICC 8th edition
• Tumors involving the EGJ with epicenter ≤2 cm into the proximal stomach are staged as esophageal cancer
• Stage groupings are histology-specific (SCC vs. adenocarcinoma)

---

Regional Lymph Nodes

• Staging based on number, not location, of involved nodes
• Regional nodes range from periesophageal to celiac

---

Locoregional Staging

---

Endoscopic Ultrasound (EUS)

• Most accurate for staging invasive esophageal cancer
• Visualizes tumor relation to esophageal wall layers

T Staging via EUS

• T1a – Limited to mucosa
• T2 – Invades muscularis propria
• T3 – Invades adventitia
• T4a – Involves resectable structures (pleura, pericardium)
• T4b – Involves unresectable structures (aorta, vertebral body)
• Tumor-induced stenosis may prevent full EUS evaluation
• Esophageal dilation for staging is controversial due to perforation risk

---

Nodal Staging via EUS

• Malignant features include:
  • 10 mm width
  • Round shape
  • Smooth border
  • Echo-poor pattern
• EUS-FNA or FNB confirms malignancy in accessible nodes
• Sensitivity and specificity >85%
• Celiac nodes are considered regional (not distant) in current staging

---

Bronchoscopy and Laryngoscopy

• Bronchoscopy – For upper/cervical SCC, detects airway invasion
• Laryngoscopy – For cervical SCC, assesses local extent and synchronous tumors

---

Evaluation for Distant Metastases

• Common metastatic sites:
  • Liver
  • Lungs
  • Bones
  • Adrenal glands

Imaging Modalities

• EUS – Detects <1 cm liver metastases, ascites
• PET/CT – Superior for occult metastases; guides treatment in 5–20% of cases
• Contrast-enhanced CT – Limited sensitivity for small or peritoneal metastases

PET/CT Notes

• Poor spatial resolution for tumor depth or nodal involvement
• Integrated PET/CT preferred over PET alone
• SUV may have prognostic value, but its clinical utility is uncertain
• Suspicious PET findings require biopsy confirmation due to false positives

---

PET Restaging After Induction Therapy

• Detects distant metastases post-chemoradiotherapy in ~8%
• May help avoid unnecessary surgery
• May indicate response to therapy and guide further treatment

---

Laparoscopy and Thoracoscopy

• Used for staging EGJ and distal esophageal tumors
• Especially valuable for suspected peritoneal metastases
• Laparoscopic ultrasound may improve accuracy for T, N, and M staging

Clinical Practice Variability

• NCCN – Laparoscopy optional
• ESMO – Recommended for T3/T4 EGJ adenocarcinomas
• SAGES – Optional for resectable early-stage cases

---

Other Tests

• Routine brain imaging not recommended unless symptomatic
• Brain metastases remain rare, more frequent in adenocarcinoma cohorts

TNM Staging – Esophagus and EGJ Cancers

---

Primary Tumor (T) – SCC and Adenocarcinoma

• TX: Tumor cannot be assessed
• T0: No evidence of primary tumor
• Tis: High-grade dysplasia (malignant cells confined to epithelium)
• T1: Invades lamina propria, muscularis mucosae, or submucosa
  • T1a: Invades lamina propria or muscularis mucosae
  • T1b: Invades submucosa
• T2: Invades muscularis propria
• T3: Invades adventitia
• T4: Invades adjacent structures
  • T4a: Invades pleura, pericardium, azygos vein, diaphragm, or peritoneum (potentially resectable)
  • T4b: Invades aorta, vertebral body, airway (unresectable)

---

Regional Lymph Nodes (N) – SCC and Adenocarcinoma

• NX: Nodes cannot be assessed
• N0: No regional lymph node metastasis
• N1: Metastases in 1–2 regional nodes
• N2: Metastases in 3–6 regional nodes
• N3: Metastases in ≥7 regional nodes

---

Distant Metastasis (M)

• M0: No distant metastasis
• M1: Distant metastasis present

---

Histologic Grade (G)

• GX: Grade cannot be assessed
• G1: Well differentiated
• G2: Moderately differentiated
• G3: Poorly differentiated / undifferentiated

---

Tumor Location (SCC Only)

• X: Location unknown
• Upper: Cervical esophagus to lower border of azygos vein
• Middle: Lower azygos vein to lower inferior pulmonary vein
• Lower: Lower inferior pulmonary vein to stomach (includes EGJ)

Note: Location is based on epicenter of the tumor in the esophagus.

---

Clinical T1N0 and T2N0 Thoracic Esophageal Cancer

---

Clinical T1N0 Disease

• Includes patients with clinical Tis or T1N0 thoracic adenocarcinoma or squamous cell carcinoma (SCC).
• Initial treatment:
  • Surgical resection (esophagectomy or endoscopic resection).
  • Non-surgical candidates: radiation therapy ± chemotherapy.
• Postoperative evaluation: Assess for need of adjuvant therapy based on pathology.

---

Clinical T2N0 Disease

• For most patients with resectable T2N0 thoracic esophageal cancer (regardless of histology):
  • Recommend combined modality therapy (e.g. CRT) over surgery alone.
• Low-risk SCC (well-differentiated, <2 cm, no lymphovascular invasion):
  • Upfront surgery is an acceptable option.
• Patients completing:
  • Combined modality therapy: Evaluate for surgical resection.
  • Surgery: Evaluate for adjuvant therapy based on pathology.

---

Clinical Decision Controversy

• Expert guidelines vary:
  • Some recommend initial CRT for SCC and either CRT or neoadjuvant chemotherapy for adenocarcinomas (especially distal esophagus or GEJ).
  • NCCN guidelines:
    • Support initial resection for well-differentiated lesions <3 cm.
    • Recommend CRT for high-risk features in either histology.
  • ASCO (2020):
    • Suggest initial surgery for low-risk T2N0 lesions (well-differentiated, <2 cm).

---

Evidence Limitations

• Limited representation of T2N0 patients in major CRT trials.
• FFCD 9901: No survival benefit of CRT over surgery alone in stage I–II esophageal/GEJ cancers; study possibly underpowered.

---

Role of Preoperative Staging

• Preoperative staging is inaccurate:
  • Correct in only 14% of patients.
  • 50% were understaged; 36% overstaged.
• Improved staging modalities needed (e.g., EUS, endoscopic resection).

---

Summary

• Treatment for T1N0: Surgery or endoscopic resection; CRT for non-surgical candidates.
• Treatment for T2N0: Combined modality therapy preferred; surgery alone may be acceptable in well-selected, low-risk cases.
• Accurate staging and individualized risk assessment are critical.

Clinical T3-4 or Node-Positive Disease

---

Suggested Initial Approach

• Combined modality therapy is preferred over surgery alone for resectable cT3-4 or node-positive thoracic esophageal cancer, regardless of histology.

Adenocarcinoma

• For younger, fit patients: perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) is suggested.
• For older or comorbid patients: neoadjuvant chemoradiation (CRT) is an appropriate alternative.
• Patients treated with CRT followed by surgery should be considered for adjuvant immunotherapy if no pathological complete response (pCR) is achieved.

Squamous Cell Carcinoma (SCC)

• Initial therapy with CRT is suggested.
• Post-treatment, evaluate for surgery or nonoperative management based on clinical response.
• After surgery, assess the need for adjuvant therapy.

Chemoradiation Details

• Concurrent CRT with weekly carboplatin plus paclitaxel is preferred.
• FOLFOX may be used as an alternative radiosensitizer.
• The standard radiation dose is 50.4 Gy in 1.8 Gy daily fractions over 5 weeks.

Role of Surgery

• For adenocarcinoma: surgery is recommended after CRT.
• For SCC: surgery is preferred, but nonoperative management may be considered in cases of complete clinical response and high surgical risk.
• CRT alone remains a valid option for non-surgical candidates.

PET Scans

• Post-induction PET scans should not be solely used to decide against surgery.

Surgery Alone

• Five-year survival with surgery alone is about 30–46% in node-negative SCC but only 15% with node-positive disease.
• High recurrence rates have led to the integration of CRT.

Radiation Therapy Alone

• Radiation therapy alone is outdated and less effective than CRT.
• IMRT and 3D-CRT improve precision and reduce toxicity but are used in combination therapies.

Preoperative Chemoradiation

• Improves survival and resection quality compared to surgery alone.
• CROSS, CALGB 9781, and NEOCRTEC5010 trials confirm benefits of preoperative CRT.

Concurrent CRT Regimens

• Weekly carboplatin plus paclitaxel is better tolerated than cisplatin/5-FU combinations.
• RTOG 85-01 and INT 0123 support CRT over RT alone.

IMRT vs 3D-CRT

• IMRT offers better sparing of normal tissues and reduced side effects compared to 3D-CRT.
• Suitable target volume and planning are essential to avoid geographic miss.

Radiation Schedules

• Standard: 50.4 Gy in 1.8 Gy fractions.
• Palliative schedules: 40–45 Gy with 2.5 Gy daily fractions for inoperables.

Intensification of Preoperative Therapy

• Adding induction chemotherapy before CRT may improve pCR and survival.
• The German POET trial showed promising results for induction chemo followed by CRT.
• Further randomized trials are needed to confirm benefits.

Necessity of Surgery

• Surgery is generally recommended even in responders to CRT.
• SCC patients with complete response may avoid surgery, especially if surgical risk is high.
• Definitive CRT is appropriate for non-surgical candidates.

Adenocarcinoma vs SCC

• Adenocarcinoma: retrospective data favor surgery after CRT.
• SCC: data support CRT alone in selected cases.
• MD Anderson nomogram may help guide decisions in adenocarcinoma patients.

Use of PET After CRT

• Data are inconsistent and PET should not replace histologic confirmation.
• It may help identify non-responders early in induction chemotherapy.

Nonresponders

• For patients not responding to CRT, surgery is essential if resectable.

Timing of Surgery

• Ideally, surgery should occur 5–7 weeks after CRT.
• Early surgery (<4 weeks) increases complication risk.
• Delays beyond 10 weeks are controversial, with mixed survival outcomes.

Neoadjuvant Chemotherapy

• Some trials show benefit, others do not.
• MAGIC, MRC OE2, and FFCD trials support its use.
• Meta-analyses show modest OS benefit, particularly for GEJ tumors.

Chemotherapy vs Chemoradiation

• For adenocarcinoma: perioperative FLOT is preferred in younger, fit patients.
• For SCC: CRT is generally better tolerated and results in higher pCR rates.
• ESOPEC trial: FLOT superior to CRT in OS for adenocarcinoma.

Neoadjuvant vs Postoperative Chemotherapy

• JCOG9907 showed preoperative chemotherapy improved OS compared to postoperative.

Local Control

• CRT followed by surgery results in better locoregional control than surgery or CRT alone.
• CROSS and related trials show reduced recurrence with combined therapy.

Role of postoperative (adjuvant) therapy

---

After preoperative therapy

• Patients with a pathological complete response (pCR) after CRT do not need further therapy and proceed to surveillance.
• For patients with residual disease after CRT, adjuvant nivolumab for up to one year is suggested.
• If nivolumab is not suitable, options include:
  • Post-treatment surveillance (only for ypN0-1 tumors)
  • Adjuvant chemotherapy with different agents than preoperative CRT (e.g., FOLFOX if CRT included carboplatin + paclitaxel)

Nivolumab

• CheckMate 577 trial showed doubling of disease-free survival (22.4 vs 11 months) with nivolumab in patients with residual disease.
• The benefit was independent of histology, PD-L1 status, or tumor location.
• Most adverse effects were mild (grades 1–2); only 9% discontinued treatment.
• Approved by the FDA for patients with residual disease after neoadjuvant CRT and surgery.

Chemotherapy

• Retrospective studies and meta-analyses suggest improved survival with adjuvant chemotherapy after CRT and surgery.
• Best given with agents different from the preoperative regimen.
• Examples: use FOLFOX if pre-op was carboplatin + paclitaxel, and vice versa.

No prior neoadjuvant therapy

• For pT3/T4 or node-positive esophageal adenocarcinoma: adjuvant chemotherapy is suggested.
• For high-risk pT2N0 adenocarcinoma: adjuvant chemotherapy is also suggested.
• Postoperative CRT is not recommended due to lack of clear data.
• For SCC: postoperative therapy is only considered if margins are positive.

Chemoradiation

• For node-positive GEJ adenocarcinoma: postoperative CRT is standard in the U.S.
• For thoracic SCC: evidence is limited, but some studies suggest benefit.

Chemotherapy alone

• May be used if no preoperative therapy was given.
• Japanese RCT in SCC showed better DFS with adjuvant chemotherapy, but OS was similar.
• Used mostly in analogy to gastric cancer treatment.

Post-treatment cancer surveillance

Patterns of failure

• SCCs in upper/mid-thoracic esophagus relapse locally; adenocarcinomas relapse distantly.
• Neoadjuvant-treated patients tend to relapse earlier than surgery-alone patients.
• After CRT, local recurrences are more common and salvage surgery may be beneficial.

Surveillance strategy

• No randomized data to support routine surveillance improves survival.
• Suggested follow-up:
  • History/physical and labs every 4 months for 3 years
  • CT chest/abdomen every 4 months
  • Endoscopy only in specific cases (e.g., Barrett’s, positive margin, stricture)
• NCCN guidelines:
  • Clinical visits every 3–6 months (years 1–2), every 6–12 months (years 3–5), then yearly
  • CBC and labs as indicated
  • Imaging and endoscopy as indicated
  • Dilation for strictures
  • Nutrition support
• ESMO guidelines:
  • Focus on symptoms, nutrition, psychosocial aspects
  • Consider 3-month follow-up with endoscopy and CT after CRT-only treatment
• Reduce CT scan frequency to minimize radiation exposure, especially in younger patients.

Locally Advanced Unresectable or Inoperable Esophageal Cancer

---

Definitive chemoradiation

• Chemoradiation therapy (CRT) improves overall survival and dysphagia palliation compared to radiation therapy (RT) alone in unresectable cases.
• For severe dysphagia, endoscopic therapy may be used before CRT.

Benefits

• RTOG 85-01 trial demonstrated CRT’s superiority: median overall survival of 14 vs. 9 months and 5-year overall survival of 27% vs. 0% compared to RT alone.
• CRT reduced both persistent disease and distant metastasis rates versus RT alone.
• Based on these results, CRT became the standard of care for inoperable cases.

Palliation of dysphagia

• Swallowing typically improves within 2–4 weeks of starting CRT.
• Benefits are long-lasting, even in palliative cases.

Radiosensitizing chemotherapy

• Weekly carboplatin plus paclitaxel is the preferred regimen due to better tolerability.
• FOLFOX offers an alternative, though it requires an infusional fluorouracil pump.

Carboplatin plus paclitaxel

• CROSS trial demonstrated high pathological complete response rates and improved overall survival in resectable disease, findings now applied to unresectable cases.

FOLFOX

• PRODIGE5/ACCORD17 trial showed progression-free survival comparable to fluorouracil/cisplatin, with different toxicity patterns.

Regimens not used

• Fluorouracil plus cisplatin carries higher toxicity and administrative burden.
• CAPOX, S-1, cetuximab, and HER2-targeted therapies remain investigational or are not recommended.

Radiation therapy dosing

• Standard dose ranges from 50.4 to 54 Gy in 1.8–2 Gy fractions.
• Higher doses offer no survival benefit and increase toxicity (shown in RTOG 94-05 and ARTDECO trials).
• Brachytherapy is not routinely recommended due to limited evidence and toxicity concerns.

Radiation complications

Tracheoesophageal fistula

• More common in squamous cell carcinoma; rare but serious.
• Risk increases when stents precede radiation therapy.
• Treatment involves stenting or, occasionally, surgical intervention.

Esophageal strictures

• Can be benign or malignant; benign cases respond to dilation.

Management after definitive CRT

Posttreatment evaluation

• Consists of clinical history, PET-CT (after 5–8 weeks), and endoscopic evaluation with biopsy.
• Complete clinical response (cCR) means no detectable disease clinically or pathologically.

cCR patients

• Surveillance is preferred to surgery.
• SANO trial showed surveillance was noninferior to surgery for overall survival.

No cCR or recurrent disease

• Management options include endoscopy, systemic therapy, clinical trials, or supportive care.
• Salvage esophagectomy carries high risk with limited benefit.

Persistent/recurrent disease

• CRT-resistant disease carries poor prognosis.
• Treatment focuses on systemic therapy or local palliative measures.

Investigational strategies

Induction chemotherapy + CRT

• Shows no clear benefit while adding toxicity.

Immunotherapy + CRT

• Currently under investigation.

Ineligible for CRT

• Options include radiation alone, endoscopic intervention, or brachytherapy for palliation.

Endoscopic interventions

• Stenting provides most effective relief for malignant dysphagia.
• Dilation offers temporary benefit but carries risks.
• Alternative options include PDT, APC, and cryotherapy in select cases.

Brachytherapy

• Effective but limited in use; best for patients with prognosis exceeding 6 months.

No role for palliative surgery

• High morbidity and mortality make it inferior to modern palliative approaches.

---

Key Differential Diagnoses of Esophageal Cancer

---

• Achalasia
  • Presents with slowly progressive dysphagia to solids and liquids.
  • Often involves long-standing regurgitation.
  • Pseudoachalasia (tumor at the gastroesophageal junction) must be ruled out, as it mimics primary achalasia but is malignant.
• Gastroesophageal Reflux Disease (GERD)
  • Symptoms include dysphagia, heartburn, and regurgitation.
  • Usually lacks rapid progression and significant weight loss seen in cancer.
• Esophageal Stricture
  • Benign narrowing due to chronic GERD or caustic injury.
  • Presents with progressive dysphagia to solids.
  • Generally slower progression and no systemic symptoms.
• Esophagitis
  • Caused by reflux, infection (Candida, HSV), or medications.
  • Presents with odynophagia and dysphagia.
  • Differentiated by endoscopy and biopsy.
• Barrett’s Esophagus
  • Premalignant condition from chronic GERD.
  • May present with similar symptoms.
  • Diagnosed via endoscopic biopsy.
  • Increases risk for esophageal adenocarcinoma.
• Diffuse Esophageal Spasm and Other Motility Disorders
  • Includes scleroderma, myasthenia gravis.
  • Causes intermittent dysphagia to solids and liquids.
  • Typically lacks the progressive course of cancer.
• Esophageal Webs and Rings
  • Includes conditions like Plummer-Vinson syndrome.
  • Usually cause intermittent dysphagia to solids.
  • Often non-progressive.
• Zenker’s Diverticulum
  • Presents with oropharyngeal dysphagia, regurgitation of undigested food, and halitosis.
  • Diagnosed with barium swallow.
• Neurological Disorders
  • Stroke, ALS, Parkinsonism may cause oropharyngeal dysphagia.
  • Usually accompanied by other neurological symptoms.
• Systemic Sclerosis (Scleroderma)
  • Leads to esophageal dysmotility and reflux.
  • Due to smooth muscle atrophy and lower esophageal sphincter incompetence.
• Infectious Esophagitis
  • Common in immunocompromised patients.
  • Caused by pathogens like Candida, HSV, CMV.
  • Presents with odynophagia and dysphagia.
  • Characteristic endoscopic appearance helps with diagnosis.

Prognostic Factors

---

• Tumor stage at diagnosis: Most significant determinant; early-stage disease has markedly better outcomes.
• Histological subtype: Adenocarcinoma and SCC have similar poor prognoses in advanced stages.
• Tumor location and length
• Lymph node involvement
• Patient performance status and comorbidities
• Response to neoadjuvant therapy

The overall 5-year survival rate remains low (~15%), underscoring the importance of early detection and advances in multimodal therapy.

---